Preclinical efficacy of prexasertib in acute lymphoblastic leukemia

The addition of molecularly targeted therapies to current chemotherapy regimens may improve acute lymphoblastic leukemia (ALL) outcomes and reduce acute and late toxicities. Checkpoint kinase 1 (CHK1) orchestrates cell cycle checkpoint control in the setting of DNA damage. CHK1 is expressed in both...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2021-09, Vol.194 (6), p.1094-1098
Hauptverfasser:	Ostergaard, Jason, Jonart, Leslie M., Ebadi, Maryam, Koppenhafer, Stacia L., Gordon, David J., Gordon, Peter M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Animals Cell Line, Tumor Cell Proliferation - drug effects Checkpoint Kinase 1 - antagonists & inhibitors Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Deoxycytidine - therapeutic use Drug Synergism Hematology Humans Leukemia Lymphatic leukemia Mice Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyrazines - pharmacology Pyrazines - therapeutic use Pyrazoles - pharmacology Pyrazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!